Novel Vectors for Dendritic Cell Transduction
Abstract
The development of vaccine approaches for breast cancer has the potential to provide an adjuvant therapy with low toxicity for patients at risk for disease recurrence. We are investigating novel vaccine strategies for breast cancer. The target tumor antigen is carcinoembryonic antigen (CEA), which is highly expressed in most breast tumors. Dendritic cells (DOs) show promise for cancer immunotherapy due to their critical role in mediating immune response. Development of an optimal DC transduction protocol for tumor antigen presentation would represent a significant advancement in DC-based vaccination strategies. We are investigating methods of DC transduction and antigen modification that will elicit the most potent anti-tumor immune response. Tumor challenge and tumor therapy experiments are performed using a syngeneic adenocarcinoma cell line which expresses human CEA ?MC38-CEA-2). Because the ability to break tolerance to self antigens is critical for the success of this cancer immunotherapy approach, a CEA-transgenic mouse model will also be used.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2002
- Accession Number
- ADA420272
Entities
People
- Theresa V. Strong
Organizations
- University of Alabama